Get the Stockscreener App
48.07
0.90%
0.43
Overview
News
Price History
Option Chain
Why NVO Down?
Discussions
Forecast
Stock Split
Dividend History
Novo Nordisk Adr stock is traded at $48.07, with a volume of 19.32M.
It is up +0.90% in the last 24 hours and up +8.78% over the past month.
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
See More
Previous Close:
$47.64
Open:
$47.12
24h Volume:
19.32M
Relative Volume:
1.25
Market Cap:
$212.80B
Revenue:
$50.91B
Net Income/Loss:
$18.95B
P/E Ratio:
11.28
EPS:
4.261
Net Cash Flow:
$1.92B
1W Performance:
+11.30%
1M Performance:
+8.78%
6M Performance:
-8.26%
1Y Performance:
-29.00%
1-Day Range:
$46.99
$48.50
1-Week Range:
$43.90
$48.50
52-Week Range:
$35.12
$71.80
Novo Nordisk Adr Stock (NVO) Company Profile
Name
Novo Nordisk Adr
Sector
Industry
Phone
-
Address
-
Compare NVO vs LLY, JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NVO
Novo Nordisk Adr
|
48.07 | 212.80B | 50.91B | 18.95B | 1.92B | 4.261 |
LLY
Lilly Eli Co
|
1,208.12 | 1.08T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
254.66 | 613.02B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
253.35 | 447.62B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
128.66 | 317.77B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
155.41 | 296.54B | 54.66B | 13.58B | 16.05B | 7.0171 |
Novo Nordisk Adr Stock (NVO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-26-26 | Initiated | Wolfe Research | Peer Perform |
| Mar-18-26 | Initiated | Bernstein | Outperform |
| Mar-10-26 | Downgrade | TD Cowen | Buy → Hold |
| Mar-03-26 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Mar-02-26 | Downgrade | Goldman | Buy → Neutral |
| Feb-24-26 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-24-26 | Downgrade | Kepler | Buy → Hold |
| Feb-23-26 | Downgrade | Deutsche Bank | Buy → Hold |
| Feb-12-26 | Upgrade | Jefferies | Underperform → Hold |
| Jan-27-26 | Initiated | Citigroup | Neutral |
| Dec-08-25 | Downgrade | Argus | Buy → Hold |
| Oct-27-25 | Resumed | Jefferies | Underperform |
| Oct-01-25 | Upgrade | HSBC Securities | Hold → Buy |
| Sep-29-25 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Sep-17-25 | Upgrade | Berenberg | Hold → Buy |
| Sep-16-25 | Upgrade | Rothschild & Co Redburn | Neutral → Buy |
| Sep-09-25 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Aug-13-25 | Upgrade | BNP Paribas Exane | Underperform → Neutral |
| Aug-05-25 | Downgrade | UBS | Buy → Neutral |
| Jul-31-25 | Downgrade | HSBC Securities | Buy → Hold |
| Jul-30-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Apr-17-25 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Mar-13-25 | Upgrade | Kepler | Hold → Buy |
| Mar-03-25 | Downgrade | Stifel | Buy → Hold |
| Feb-12-25 | Initiated | Morgan Stanley | Equal-Weight |
| Jan-06-25 | Upgrade | Bernstein | Underperform → Mkt Perform |
| May-30-24 | Initiated | Goldman | Buy |
| Apr-12-24 | Initiated | BMO Capital Markets | Outperform |
| Jan-23-24 | Initiated | Morgan Stanley | Overweight |
| Jan-16-24 | Resumed | UBS | Neutral |
| Dec-01-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-02-23 | Initiated | Argus | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jul-15-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-28-22 | Downgrade | UBS | Neutral → Sell |
| Jun-27-22 | Upgrade | Exane BNP Paribas | Underperform → Neutral |
| Jun-07-22 | Upgrade | JP Morgan | Neutral → Overweight |
| May-31-22 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-25-22 | Upgrade | Cowen | Market Perform → Outperform |
| Apr-12-22 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Mar-16-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Jan-25-22 | Downgrade | Liberum | Hold → Sell |
| Dec-20-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-17-21 | Downgrade | Deutsche Bank | Buy → Hold |
| Jan-20-21 | Downgrade | Credit Suisse | Outperform → Neutral |
| Jan-15-21 | Initiated | Deutsche Bank | Buy |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jul-06-20 | Downgrade | BofA Securities | Buy → Neutral |
| May-11-20 | Downgrade | UBS | Buy → Neutral |
| May-04-20 | Initiated | Cowen | Market Perform |
| Mar-16-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jan-03-20 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-18-19 | Upgrade | Barclays | Equal Weight → Overweight |
| Sep-17-19 | Upgrade | Citigroup | Neutral → Buy |
| Aug-30-19 | Downgrade | Jefferies | Hold → Underperform |
| Jun-20-19 | Downgrade | Deutsche Bank | Buy → Hold |
| Jun-11-19 | Upgrade | Barclays | Underweight → Equal Weight |
| Apr-29-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jan-29-19 | Initiated | Exane BNP Paribas | Outperform |
| Dec-11-18 | Resumed | Jefferies | Hold |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Dec-29-17 | Upgrade | JP Morgan | Underweight → Neutral |
| Dec-06-17 | Upgrade | BofA/Merrill | Neutral → Buy |
| Dec-01-17 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-25-17 | Downgrade | Exane BNP Paribas | Outperform → Neutral |
| Sep-06-17 | Upgrade | BofA/Merrill | Underperform → Neutral |
View All
Novo Nordisk Adr Stock (NVO) Latest News
Opinion: Pfizer Is a Fantastic Dividend Stock for Income Investors to Buy Right Now - The Motley Fool
NOVA Forecast — Price Target — Prediction for 2027 - TradingView
Novo Nordisk consensus shifts after analyst moves, shares trade lower in Europe - Ad-hoc-news.de
Novo Nordisk A/S ADR B Unsponsored Brazilian Depositary Receipt Repr 0.125 ADR B - TradingView
Novo Nordisk consensus after Morningstar downgrade, shares remain in focus on NYSE and Copenhagen - Ad-hoc-news.de
Non-controlling/minority interest of Novo Nordisk A/S ADR Cert Deposito Arg Repr 0.142857 ADR-B – BCBA:NVOC - TradingView
NVO Stock Quote Price and Forecast - CNN
Novo Nordisk (NYSE: NVO) repurchases 20,959,179 shares in 2026 - Stock Titan
Novo Nordisk updates analyst targets, shares stay in S&P 500 focus - Ad-hoc-news.de
Novo Nordisk wins key South Africa ruling, shares extend obesity-drug lead - Ad-hoc-news.de
Wegovy from Novo Nordisk A/ S (ADR)weekly injection reshapes obesity care - Ad-hoc-news.de
European ADRs Open The Week Higher In US Trading - Finimize
Novo Nordisk A/Sshare repurchase programme - Finansavisen
Novo Nordisk StockAnalyst consensus and GLP-1 momentum - Ad-hoc-news.de
Novo Nordisk (NYSE:NVO) Faces Cyber Breach While Pushing Oral Wegovy Into China - Sahm
Why Novo Nordisk’s Wegovy weekly injection changes daily routines - Ad-hoc-news.de
Why Novo Nordisk’s Ozempic FlexTouch pen keeps changing everyday routines - Ad-hoc-news.de
Novo Nordisk Data Breach: Hackers Claim To Have Stolen Drug Research, Trial Data And AI Models - Sahm
Novo Nordisk A/ S Stock (DK0062498333): China Wegovy filing puts the stock in focus - Ad-hoc-news.de
Novo Nordisk A/ S Stock (DK0062498333): Buyback Update Puts Capital Returns In Focus - Ad-hoc-news.de
Novo Nordisk (NVO) repurchases 19.9M B shares under 2026 plan - Stock Titan
Novo Nordisk A/ S Stock (DK0060534915): Technical picture draws investor focus - AD HOC NEWS
Novo Nordisk’s CagriSema Breakthrough Expands Growth Story Beyond Diabetes and Obesity - Sahm
Novo Nordisk A/S Stock (DK0060534915): Wegovy tablet approval and ADRs in focus after late-week gain - Ad-hoc-news.de
Market news - investments.halifax.co.uk
Novo Nordisk Wegovy pill draws 10,000 UK waitlist ahead of approvalBloomberg - Investing.com Australia
Total operating expenses of Novo Nordisk A/S ADR Cert Deposito Arg Repr 0.142857 ADR-B – BCBA:NVOD - TradingView
Assessing Novo Nordisk (NYSE:NVO) Valuation After Recent Share Weakness And GLP‑1 Growth Questions - simplywall.st
Novo Nordisk CEO Hints Semaglutide Could Be More Than A Weight-Loss Drug: 'A Bit Of A Longevity Game' - Sahm
Oral GLP-1 obesity drugs see rapid early adoption, Bernstein survey shows - Investing.com Nigeria
Novo Nordisk A/S stock (DK0062498333): Ozempic boom meets fresh obesity data and US pricing debate - AD HOC NEWS
European ADRs Started The Week In The Green - Finimize
Novo Nordisk ADR's decline widens rapidly to 3.8%, hitting a new intraday low - Bitget
Novo Nordisk stock falls on ADA conference readthrough - Investing.com
Novo Nordisk Wegovy Trial With Veru Adds Underappreciated Obesity Angle - Sahm
Total operating expenses of Novo Nordisk A/S ADR Cert Deposito Arg Repr 0.142857 ADR-B – BCBA:NVO - TradingView
Novo Nordisk Adr Stock (NVO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.56%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):